News

Filter

Current filters:

Janssen-CilagNeurological

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

European Commission OKs J&J’s Xeplion for schizophrenia

10-03-2011

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), says…

ElanEuropeJanssen-CilagJohnson & JohnsonNeurologicalPharmaceuticalRegulationXeplion

Johnson & Johnson’s Invega first antipsychotic for schizoaffective disorder approved in EU

05-01-2011

Belgium-based Janssen-Cilag International, part of US health care giant Johnson & Johnson (NYSE: JNJ),…

EuropeInvegaJanssen-CilagJohnson & JohnsonNeurologicalPharmaceuticalRegulation

J&J unit Janssen-Cilag withdraws MAA for Comfyde based on negative CHMP feedback

22-01-2010

Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johns, has withdrawn its…

EuropeJanssen-CilagNeurologicalPharmaceuticalRegulation

COMPANY SPOTLIGHT

Menarini

Back to top